Ren C - Search Results

1

Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.

Zhang L, Zhang J, Wang J, Ren C, Tang P, Ouyang L, Wang Y. Zhang L, et al. Among authors: ren c. Eur J Med Chem. 2022 Mar 15;232:114176. doi: 10.1016/j.ejmech.2022.114176. Epub 2022 Feb 3. Eur J Med Chem. 2022. PMID: 35151222 Review.

2

Molecular glues targeting protein degradation pathways for drug discovery.

Ren C, Gan X, Zhou H, Li J, Zhang J. Ren C, et al. Future Med Chem. 2022 Jan;14(3):135-137. doi: 10.4155/fmc-2021-0229. Epub 2021 Nov 15. Future Med Chem. 2022. PMID: 34779647 No abstract available.

3

DYRK1A inhibitors for disease therapy: Current status and perspectives.

Liu T, Wang Y, Wang J, Ren C, Chen H, Zhang J. Liu T, et al. Among authors: ren c. Eur J Med Chem. 2022 Feb 5;229:114062. doi: 10.1016/j.ejmech.2021.114062. Epub 2021 Dec 21. Eur J Med Chem. 2022. PMID: 34954592 Review.

4

Targeting EZH2 for cancer therapy: From current progress to novel strategies.

Zeng J, Zhang J, Sun Y, Wang J, Ren C, Banerjee S, Ouyang L, Wang Y. Zeng J, et al. Among authors: ren c. Eur J Med Chem. 2022 Aug 5;238:114419. doi: 10.1016/j.ejmech.2022.114419. Epub 2022 Apr 30. Eur J Med Chem. 2022. PMID: 35569264 Review.

5

Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.

Zhang Y, Hu Z, Zhang J, Ren C, Wang Y. Zhang Y, et al. Among authors: ren c. Eur J Med Chem. 2022 Aug 5;238:114524. doi: 10.1016/j.ejmech.2022.114524. Epub 2022 Jun 8. Eur J Med Chem. 2022. PMID: 35696861 Review.

6

Current progress and novel strategies that target CDK12 for drug discovery.

Lei P, Zhang J, Liao P, Ren C, Wang J, Wang Y. Lei P, et al. Among authors: ren c. Eur J Med Chem. 2022 Oct 5;240:114603. doi: 10.1016/j.ejmech.2022.114603. Epub 2022 Jul 12. Eur J Med Chem. 2022. PMID: 35868123 Review.

7

Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.

Zhou Z, Zhang J, Zhou E, Ren C, Wang J, Wang Y. Zhou Z, et al. Among authors: ren c. Eur J Med Chem. 2022 Oct 5;240:114595. doi: 10.1016/j.ejmech.2022.114595. Epub 2022 Jul 8. Eur J Med Chem. 2022. PMID: 35868125 Review.

8

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.

Fang Y, Wang J, Zhao M, Zheng Q, Ren C, Wang Y, Zhang J. Fang Y, et al. Among authors: ren c. J Med Chem. 2022 Sep 8;65(17):11454-11477. doi: 10.1021/acs.jmedchem.2c00844. Epub 2022 Aug 25. J Med Chem. 2022. PMID: 36006861 Review.

9

Targeting FGFRs for tumor therapy: current status and novel strategies.

Dong Y, Ren C, Zhu M, Zhang D, Wang T, Zhang J, Wang J, Mao W, Long F. Dong Y, et al. Among authors: ren c. Future Med Chem. 2022 Dec;14(24):1923-1941. doi: 10.4155/fmc-2022-0194. Epub 2022 Nov 30. Future Med Chem. 2022. PMID: 36449352 Review.

10

Novel targeted protein degradation technologies as a therapeutic strategy for neurodegenerative diseases.

Ren C, Liu J, Pu S, Zhou H, Li J, Zhang J. Ren C, et al. Future Med Chem. 2023 Mar;15(5):395-397. doi: 10.4155/fmc-2023-0035. Epub 2023 Mar 31. Future Med Chem. 2023. PMID: 36999360 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,436 results

Search Page

Filters